Tetrahexylammonium

Tetrahexylammonium

SCHEMBL444046

CCCCCC[N+](CCCCCC)(CCCCCC)CCCCCC.O=S(=O)([O-])[O-].[H+]

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Tetrahexylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.65
ALDH1A1 P00352 1/20 0.62
TP53 P04637 1/20 0.62
CYP3A4 P08684 1/20 0.62
ALOX15 P16050 1/20 0.62
TSHR P16473 1/20 0.62
ALOX12 P18054 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
HIF1A Q16665 1/20 0.62
HSD17B10 Q99714 1/20 0.62
SLC22A2 O15244 1/20 0.60
DNM1 Q05193 6/20 0.56
LSS P48449 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL4372098 1.00 SLC22A1 (0.65) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL1697122 1.00 SLC22A1 (0.65) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Tetrahexylammonium SCHEMBL3641187 0.98 SLC22A1 (0.62) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL9792101 0.98 SLC22A1 (0.62) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL11344200 0.97 SLC22A1 (0.68) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Tetrahexylammonium SCHEMBL4146123 0.97 SLC22A1 (0.68) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Tetrapentylammonium SCHEMBL6261128 0.97 SLC22A1 (0.63) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL2320651 0.97 SLC22A1 (0.68) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL6262541 0.95 SLC22A1 (0.59) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Sulfuric Acid SCHEMBL6260170 0.95 SLC22A1 (0.59) SLC22A1ALDH1A1TP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119510645-A Method for detecting content of zoledronic acid concentrated solution for injection 海南葫芦娃药业集团股份有限公司 2025-02-25 CN claimed
CN-119310209-A Analysis method of related substances of zoledronic acid concentrated solution for injection 海南葫芦娃药业集团股份有限公司 2025-01-14 CN claimed
CN-110161168-B High performance liquid chromatography detection method for zoledronic acid and impurities thereof 四川科伦药物研究院有限公司 2022-12-20 CN claimed
CN-115010836-A Electrochromatic polymer, nano particles and device 吉林大学 2022-09-06 CN claimed
CN-108795407-B Electrochromic material based on action of electrochromic acid and preparation of electrochromic device 常州铱视光电科技有限公司 2021-04-16 CN claimed
CN-108949141-B Preparation method of bistable electrochromic material and application of bistable electrochromic material in preparation of electrochromic device 常州铱视光电科技有限公司 2021-02-05 CN claimed
CN-111474268-A High performance liquid chromatography detection method for foscarnet sodium and impurities thereof 武汉药品医疗器械检验所 2020-07-31 CN claimed
CN-106353425-B Method for detecting related substances in zoledronic acid injection by high performance liquid chromatography 扬子江药业集团四川海蓉药业有限公司 2020-06-02 CN claimed
EP-3267963-B1 POLYMERIZABLE DENTAL MATERIAL HAVING A PHASE TRANSFER CATALYST KETTENBACH GMBH & CO KG (DE) 2020-02-12 EP claimed
US-10307343-B2 Polymerizable dental material with a phase transfer catalyst KETTENBACH GMBH & CO. KG (DE) 2019-06-04 US claimed
US-20160262987-A1 Polymerizable Dental Material With a Phase Transfer Catalyst KETTENBACH GMBH & CO. KG (DE) 2016-09-15 US claimed
US-7541312-B2 Porous carbons from carbohydrates TDA RESEARCH, INC. (US) 2009-06-02 US claimed
US-7153635-B1 Thermally developable materials processable at lower temperatures EASTMAN KODAK COMPANY (US) 2006-12-26 US claimed
US-20050207962-A1 Porous carbons from carbohydrates TDA RESEARCH, INC. (US) 2005-09-22 US claimed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US claimed
US-12606513-B2 Formate production method, formic acid production method, and antifreezing agent production method NITTO DENKO CORPORATION (JP) 2026-04-21 US disclosed
EP-4713313-A2 TETRAHYDRONAPTHYRIDINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD Springworks Therapeutics, Inc. (US) 2026-03-25 EP disclosed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US disclosed
EP-0300922-A1 Process for the manufacture of derivatives of benzoic acid GADOT PETROCHEMICAL INDUSTRIES LTD. (IL) 1989-01-25 EP disclosed
US-4691058-A Process for producing 1-hydroxy ketones CIBA-GEIGY CORPORATION (US) 1987-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10307343-B2 Polymerizable dental material with a phase transfer catalyst PRDX4, SMOX, PRDX2 SLC22A1 924/4885ALDH1A1 1564/4885TP53 3325/4885
US-12606513-B2 Formate production method, formic acid production method, and antifreezing agent production method CA2, TAF5, HACL2 SLC22A1 2007/4885ALDH1A1 1262/4885TP53 3818/4885
US-20160262987-A1 Polymerizable Dental Material With a Phase Transfer Catalyst PRDX4, SMOX, PRDX2 SLC22A1 924/4885ALDH1A1 1564/4885TP53 3325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.